

### Recent patent applications related to antimicrobials

Patent #	Subject	Assignee	Inventor(s)	Priority application date	Publication date
WO 200405539	Methods for diagnosing sepsis disease state in a subject by determining the relative amount of mitochondrial nucleic acid in a sample; useful for treating sepsis.	University of British Columbia (Vancouver, BC Canada)	Cote H, Montaner J, O'Shaughnessy M	7/5/2002	1/15/2004
WO 200405339	Cationic peptides and related nucleic acids useful as antibacterial and antifungal agents for clinical or agricultural use. The compositions have low toxicity, are not hemolytic and have a broad spectrum of antimicrobial activity that is not affected by human serum. They are active against some antibiotic-resistant strains.	Diatos (Paris)	Arranz V, Avrameas E	7/8/2002	1/15/2004
WO 200404743	Immunostimulating agents containing chemically modified RNA that increases cytokine secretion from cells; useful for treating or preventing bacterial, viral, fungal or protozoal infections and cancer.	CureVac (Tübingen, Germany)	Hoerr I, Pascolo S, von der Mülbe F	7/3/2002	1/15/2004
WO 200403545	A pharmaceutical composition comprising a competitor of hyaluronan interactions to reduce the drug resistance of a cell; useful for treating multidrug-resistant cells, as in cancer.	Tufts University (Boston, MA, USA)	Toole BP	3/11/2003	1/8/2004
WO 200402967	New difluorothioacetamide oxazolidinones useful for treating bacterial infections caused by gram-positive bacteria (e.g., skin, eye and ear infections).	Pharmacia & Upjohn Co. (New York)	Adams WJ, Gordeev MF, Hester JB, Scott C, Singh U, Stevens JC	6/28/2002	1/8/2004
WO 200402956	New D-allyl(4-hydroxyphenyl)glycine for producing aminopyrrolidinone; useful for treating inflammatory disorders (e.g., allergic asthma). The compound possesses matrix metallo-protease and/or TNF- $\alpha$ inhibitory activity and has the ability to suppress cartilage degradation <i>in vivo</i> .	Bristol-Myers Squibb Co. (New York)	Anderson SR, Bordawekar S, Campagna S, Desikan S, Maduskuie TP, Savage SA, Waltermire RE	8/1/2002	1/8/2004
WO 200401055	A peptide nucleic acid prodrug with film-enhanced transport across cell membranes, improving the access of the PNA to potential cellular/nuclear targets; useful for combating various diseases, for example, cancer and bacterial and fungal infections.	Santaris Pharma (Hørsholm, Denmark)	Bendifallah N, Nielsen PE	6/20/2002	12/31/2003
WO 2003106454	New 1H-isoquinoline-oxazolidinone derivative with antibacterial activity; useful for the treatment or prevention of infectious disorders caused by bacteria, for example, methicillin-resistant <i>Staphylococcus aureus</i> and penicillin-resistant <i>Streptococcus pneumoniae</i> .	Orchid Chemicals & Pharmaceuticals Ltd. (Chennai, India)	Agarwal SK, Guha MK, Samuel MM	6/12/2002	12/24/2003
WO 2003106445	New sulfonated homoserine lactones that inhibit bacterial growth and act as a quorum-sensing inhibitor; useful for the treatment of bacterial infections caused by gram-negative aerobic rod bacterium.	QSI Pharma (Kgs Lyngby, Denmark)	Givskov M, Nielsen J	6/12/2002	12/24/2003
WO 2003106413	Preparation of a library of substituted oxazolidinones, involving reacting a protected oxymethyloxazolidinone in an anhydrous organic solvent to form a mixture, followed by reaction in an aqueous solvent; useful for treating microbial infections.	Synthon (Monmouth Junction, NJ, USA); Michigan State Univ. (E. Lansing, MI, USA)	Dai Z, Hollingsworth RI, Mao J, Padmakumar R, Puthuparampil K, Wang G, Zhang H	10/18/2001	12/24/2003

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, Va 22314. Tel: 1 (800) DERWENT (info@derwent.com).